Welcome to CTalk Henry
that is a million$$$$ question regarding HC !
depending upon provincial "rules" and how they play into overall HC regs....
there may be some access under compassionate care / experimental release IF there is a particularly good, pro-active and aggressive doctor in the loop who can navigate the systems for you... and this would apply to all "new" treatments and drugs.
IME ... each province / cancer center etc. seems to be its own minefield OR field of dreams
depending upon the factors mentioned.
Specifically though, a September 27, 2017 announcement Keytruda Approved as First-Line Lung Cancer Treatment in Canada
states a specific use acceptance for one application :
“Lung cancer is the leading cause of cancer death for both men and women in Canada, which makes this new indication especially significant. We look forward to working with provinces and other jurisdictions to ensure that Canadians who need immunotherapy for first-line treatment of metastatic NSLC have rapid access to Keytruda,” Chirfi Guindo, president and managing director of Merck Canada (known as MSD outside the U.S. and Canada),
How quickly this availability will translate to other indications is anybody's guess.
ANY OTHER Canucks with any other info please chime in !